Dr7.5

D-Ribose Research

40 peer-reviewed studies · Evidence score: 7.5/10

1

Purine Nucleotide Precursors in Preventing Myocardial Ischemia-Reperfusion Injury

Musial PT et al. • International journal of molecular sciences (2025)

The scope of this article is to review knowledge of the effect of purine nucleotide precursors such as D-ribose, AICAR, inosine, hypoxanthine, and adenine on myocardial ischemia-reperfusion injury and highlight potential targets for treating myocardial metabolic and mechanical dysfunction associated with ischemia-reperfusion injury by these molecules.

  • Depletion of cardiac nucleotides and compromised myocardial mechanical function are linked to both acute myocardial ischemia and decompensatory remodelling of the myocardium in heart failure.
  • Theoretically, in both acute ischemia and chronic high-demand situations associated with the development of heart failure, an imbalance in the breakdown, salvage, and synthesis of purine nucleotides results in a net loss of purine nucleotides.
  • It was found that the use of nucleotide precursors can be a potentially effective approach to diminishing ischemia-reperfusion damage.
Systematic Review
DOI
2

[Postoperative delirium in the elderly]

Wróbel M et al. • Medycyna pracy (2025)

Med Pr Work Health Saf. 2025;76(3):209-215.This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL license.

  • There is no procedure to determine the certain development of delirium.
  • The search for better methods should continue.
  • Recognising the risk of delirium allows earlier preventive measures to be taken and its consequences to be reduced.
Systematic Review
DOI
3

D-ribose metabolic disorder and diabetes mellitus

Tai Y et al. • Molecular biology reports (2024)

This systematic-review examined the effects of D-Ribose.

  • Additionally, certain in vitro experiments have indicated that exogenous D-ribose exposure could trigger apoptosis in specific cell lines.
  • This article comprehensively reviews the current advancements in D-ribose's digestion, absorption, transmembrane transport, intracellular metabolic pathways, impact on cellular behaviour, and elevated levels in diabetes mellitus.
  • It also identifies areas requiring further investigation.© 2024.
Systematic Review
DOI
4

Candidate anti-tuberculosis medicines and regimens under clinical evaluation

Hoelscher M et al. • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024)

A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB.

  • Systematic review examining D-Ribose efficacy
  • Published in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024)
  • Further research warranted to confirm findings
Systematic Review
DOI
5

Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review

Dash S et al. • Journal of biomolecular structure & dynamics (2024)

This systematic-review examined the effects of D-Ribose.

  • To date, diverse scaffolds of heterocyclic and aromatic ring systems have been reported as DprE1 inhibitors based on their interaction mode, i.e. covalent, and non-covalent inhibitors.
  • Target-based and whole-cell-based screening played an imperative role in the identification of the druggable target, DprE1, whereas the druggability of the DprE2 enzyme is not proved yet.
  • Further research warranted to confirm findings
Systematic Review
DOI
6

DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs

Paoli-Lombardo R et al. • European journal of medicinal chemistry (2024)

All rights reserved.

  • This review aims to show why Ddn and DprE1 are promising therapeutic targets and highlight nitroaromatic compounds interest in developing new anti-tuberculosis treatments active against MDR-TB and XDR-TB.
  • Despite renewed interest in the development of new anti-tuberculosis nitroaromatic compounds, pharmaceutical companies often exclude nitro-containing molecules from their drug discovery programs because of their toxic and mutagenic potential.
  • This exclusion results in missed opportunities to identify new nitroaromatic compounds and promising therapeutic targets.Copyright © 2024 Elsevier Masson SAS.
Systematic Review
DOI
7

Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V)

Quinlivan R et al. • The Cochrane database of systematic reviews (2014)

Low dose creatine (60 mg/kg/day) did not cause side-effects but high-dose creatine (150 mg/kg/day) worsened the symptoms of myalgia.Authors' conclusions Although there was low quality evidence of improvement in some parameters with creatine, oral sucrose, ramipril and a carbohydrate rich diet, none was sufficiently strong to indicate significant clinical benefit.

  • Oral ribose caused diarrhoea and symptoms suggestive of hypoglycaemia including light-headedness and hunger.
  • In one study, branched chain amino acids caused a deterioration of functional outcomes.
  • Dantrolene was reported to cause a number of adverse effects including tiredness, somnolence, dizziness and muscle weakness.
Meta-Analysisn=85
DOI
8

Ribose Intake as Food Integrator: Is It a Really Convenient Practice?

Moschini R et al. • Biomolecules (2022)

On the basis of the remarkable glycation capacity of ribose, the easily predictable cytotoxic effect of the molecule is also highlighted.

  • However, this practice still presents too many critical issues, suggesting that caution is needed.
  • In fact, there are many possible negative effects of this sugar that we believe are underestimated, if not neglected, by the literature supporting the presentation of the product to the market.
  • Here, the risks deriving from the use of free ribose as ATP source, forcing ribose-5-phosphate to enter into the pentose phosphate pathway, is emphasized.
Systematic Review
DOI
9

Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review

Bonde C et al. • The Indian journal of tuberculosis (2022)

All rights reserved.

  • Researchers working in this area have to design and come up with new potent candidates with less dose, no toxicity to combat this deadly infection.
  • This review emphasized on year wise systematic development and progress of DprE1 inhibitors.Copyright © 2021 Tuberculosis Association of India.
  • Published by Elsevier B.V.
Systematic Review
DOI
10

Synthetic molecules as DprE1 inhibitors: A patent review

Imran M et al. • Expert opinion on therapeutic patents (2021)

Four molecules are in clinical trials, which could become the drugs of the future for TB-therapy.

  • Systematic review examining D-Ribose efficacy
  • Published in Expert opinion on therapeutic patents (2021)
  • Further research warranted to confirm findings
Systematic Review
DOI
11

Purines: From Diagnostic Biomarkers to Therapeutic Agents in Brain Injury

Frenguelli BG et al. • Neuroscience bulletin (2020)

In this review we address these opportunities and the broad potential of purines as diagnostics and restorative agents.

  • The purines constitute a family of inter-related compounds that serve a broad range of important intracellular and extracellular biological functions.
  • This inter-relationship provides opportunities for both the diagnosis of energy depletion during conditions such as stroke, and the replenishment of ATP after such events.
  • In this review we address these opportunities and the broad potential of purines as diagnostics and restorative agents.
Systematic Review
DOI
12

Ribose-5-phosphate isomerases: characteristics, structural features, and applications

Chen J et al. • Applied microbiology and biotechnology (2020)

Key points • Fundamental properties of various ribose-5-phosphate isomerases (Rpis). • Differences in crystal structure and catalytic mechanism between RpiA and RpiB. • Application of Rpi as a rare sugar producer and a potential drug target.

  • To fill this gap, this paper provides detailed information about the enzymatic properties of various Rpis.
  • Furthermore, structural features, catalytic mechanism, and molecular modifications of Rpis are summarized based on extensive crystal structure research.
  • Additionally, the applications of Rpi in rare sugar production and the role of Rpi in trypanocidal drug design are reviewed.
Systematic Review
DOI
13

D-ribose and pathogenesis of Alzheimer's disease

Javed M et al. • Molecular biology reports (2020)

Thus, it is imperative that the pathogenesis and the pathways involved in AD progression are explored in the light of ribosylation and AGEs formation for identifying suitable diagnostics marker for early diagnosis or finding promising therapeutic outcomes.

  • Since, D-ribose shows highest glycation ability among other sugars hence, produces advanced glycation end products (AGEs) rapidly.
  • However, there are several other mechanisms suggested by researchers through which D-ribose may cause cognitive impairments.
  • There is a concern related to diabetic patients since they also suffer from D-ribose metabolism, may be more prone to AD risk.
Systematic Review
DOI
14

Thymidine phosphorylase in cancer aggressiveness and chemoresistance

Furukawa T et al. • Pharmacological research (2018)

Published by Elsevier Ltd.

  • We recently reported that TP-dependent thymidine catabolism contributes to tumour survival in low nutrient conditions and the pathway from thymidine to the glycolysis cascade is affected in the context of physiological and metabolic conditions.
  • In this review, we describe recent advancement in our understanding of TP, with a focus on cancer cell biology and the pharmacology of pyrimidine analogue anticancer agents.
  • This review provides comprehensive understanding of the molecular mechanism of TP function in cancer.Copyright © 2018.
Systematic Review
DOI
15

Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review

Jones K et al. • Australian and New Zealand journal of public health (2017)

Limited dietary modifications were found useful in alleviating chronic fatigue syndrome symptoms, with overall evidence narrow and inconsistent across studies.

  • Limited dietary modifications were found useful in alleviating chronic fatigue syndrome symptoms, with overall evidence narrow and inconsistent across studies.
  • Published in Australian and New Zealand journal of public health (2017)
  • Further research warranted to confirm findings
Systematic Review
DOI
16

Radiofluorinated carbohydrates for positron emission tomography

Mun J • Current topics in medicinal chemistry (2013)

The metabolism of 6-[(18)F]fluoro-L-fucose suggested that it is a bioactive analog of L-fucose in the synthesis of glycoconjugate macromolecules. 6-Deoxy-6-[(18)F]fluoro-L-ascorbic acid was evaluated to assess antioxidant function of L-ascorbic acid in rodent models of transient global ischemia and glutathione deficiency.

  • Followed by the success of 2-(18)FDG, various radiofluorinated carbohydrates have been evaluated as PET tracers, which include analogs of D-ribose, D-mannose, D-galactose, D-talose, D-fructose, D-allose, lactose, L-fucose, N-acetylneuraminic acid, and L-ascorbic acid.
  • Three radiofluorinated analogs of lactose have been designed as the substrates of the overexpressed hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein in peritumoral pancreatic tissue for early diagnosis of pancreatic cancer.
  • Further research warranted to confirm findings
Systematic Review
DOI
17

D-ribose in glycation and protein aggregation

Wei Y et al. • Biochimica et biophysica acta (2012)

D-ribose is active in glycation and induces protein aggregation, rapidly producing AGEs in vitro and in vivo.

  • D-ribose is active in glycation and induces protein aggregation, rapidly producing AGEs in vitro and in vivo.
  • Published in Biochimica et biophysica acta (2012)
  • Further research warranted to confirm findings
Systematic Review
DOI
18

Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target

Manina G et al. • Current medicinal chemistry (2010)

The heteromeric decaprenylphosphoryl-β-D-ribose 2'-epimerase thus represents a valid vulnerable antimycobacterial drug target which could result in "magic" for tuberculosis treatment.

  • Interestingly, both drugs have the same target: the heteromeric decaprenylphosphoryl-β-D-ribose 2'-epimerase encoded by dprE1 (Rv3790) and dprE2 (Rv3791) genes, respectively.
  • Arabinogalactan is a fundamental component of the mycobacterial cell wall, which covalently binds the outer layer of mycolic acids to peptidoglycan.
  • The heteromeric decaprenylphosphoryl-β-D-ribose 2'-epimerase thus represents a valid vulnerable antimycobacterial drug target which could result in "magic" for tuberculosis treatment.
Systematic Review
DOI
19

2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression

Nakajima Y et al. • Anti-cancer agents in medicinal chemistry (2009)

We review the role of D-dRib in tumor progression and discuss inhibition of D-dRib as a promising approach for chemotherapy of various tumors.

  • These findings suggest that D-dRib is a downstream mediator of TP function. 2-Deoxy-L-ribose, a stereoisomer of D-dRib, can inhibit D-dRib's anti-apoptotic effects and suppress metastasis and invasion of TP-expressing tumors in mice.
  • Although the mechanism of action of D-dRib is still unknown, the physiological activities of D-dRib have recently been reported by several groups.
  • We review the role of D-dRib in tumor progression and discuss inhibition of D-dRib as a promising approach for chemotherapy of various tumors.
Systematic Review
DOI
20

Cranial electrotherapy stimulation and fibromyalgia

Gilula MF • Expert review of medical devices (2007)

Future medicine may also include CES as an invaluable, cost-effective add-on to many facets of clinical pharmacology and medical therapeutics.

  • A form of evoked potential biofeedback, the EPFX, is a powerful stress reduction technique which assesses the chief stressors and risk factors for illness that can impede the FM patient's built-in healing abilities.
  • Future healthcare will likely expand the diagnostic criteria of FM and/or illuminate a group of related conditions and the ways in which the conditions relate to each other.
  • Future medicine for FM and related conditions may increasingly involve multimodality treatment that features CES as one significant part of the therapeutic regimen.
Systematic Review
DOI
Page 1 of 2